Developer docs
API playgroundTry for free, no card

Search company profiles

DNAtriX

Full company profile

uuid0002s6g

Namestring
DNAtriX
Websiteurl
dnatrix.com
Company typeenum
Private
Founded yearint
2005
Short descriptiontext

DNAtriX is a Houston-based clinical-stage biotechnology company developing an oncolytic virus platform to treat malignant glioma. Founded in 2005, it has raised approximately $57M in venture funding led by Morningside and DFJ Mercury to advance its engineered virus immunotherapy.

Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersSan Diego, United States
HQ citystring
San Diego
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
oncolytic virotherapy, malignant glioma treatment, glioblastoma therapeutics, tumor-selective adenovirus, brain tumor biotechnology
Industry4 codes
PRIMARYHLAAACAF
Oncology Gene Therapies (incl. oncolytic vectors & gene-modified approaches)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAKAFAH
Neuro-Oncology
SECONDARYHLAKAFAB
Medical Oncology
SECONDARYHLAKAIAL
Neuro-oncology
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Oncolytic Virotherapy / Oncology Biopharmaceuticals
Social media profiles2 records
Cost components4 values
Technology or R&D, Personnel, Operations, Others
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

DNAtriX is a biotechnology company developing an oncolytic virus platform for treating malignant glioma. The platform uses tumor-selective viruses designed to infect and destroy cancer cells in the brain while sparing healthy tissue, addressing a high-need oncology indication with limited current treatment options.

Differentiator
Functional benefit
Problem solved
Product and service1 record
1DNAtriX Oncolytic Virus Platform (malignant glioma program)
No data
Peers10 records
TypeDirect peer
Description

Replimune is a clinical-stage biotech developing a proprietary oncolytic virus platform (RP1, RP2, RP3) for solid tumors. Like DNAtriX, it builds tumor-selective oncolytic immunotherapies, advancing them both as monotherapy and in combination with checkpoint inhibitors - the most direct strategic comparable in the space.

TypeDirect peer
Description

Candel Therapeutics (formerly Advantagene) develops oncolytic virus and gene-mediated immunotherapy platforms including CAN-2409 for brain tumors and prostate cancer. It is one of the closest US-based clinical-stage competitors to DNAtriX in the glioma oncolytic virus space.

TypeDirect peer
Description

Tocagen developed Toca 511/Toca FC, a retroviral replicating vector for high-grade glioma, before being acquired by Kite/Gilead. It is the most direct historical precedent for an oncolytic/replicating virus approach specifically targeting malignant glioma.

TypeDirect peer
Description

Mustang Bio develops MB-101 (IL13Ralpha2-targeted CAR-T) and other cell/gene therapies for glioblastoma and other CNS malignancies. It represents a peer gene-therapy-for-glioma strategy, addressing the same indication using a different modality.

TypeDirect peer
Description

Plus Therapeutics develops targeted radiotherapeutics for CNS cancers including glioblastoma (Rhenium-186 NanoLiposome). It is an indirect clinical-stage peer competing for the same malignant glioma treatment paradigm with non-oncolytic modality.

TypeBroad incumbent
Description

Novocure commercializes Tumor Treating Fields (Optune) as the standard-of-care adjunct for newly diagnosed and recurrent glioblastoma. It is the dominant incumbent in malignant glioma treatment and represents both the competitive benchmark and the combination-therapy partner universe for DNAtriX.

TypeBroad incumbent
Description

Sorrento has multiple oncology franchises including oncolytic virus, antibody, and cell therapy assets touching glioma and solid tumors. It operates as a broader incumbent in the oncology gene and viral therapy space rather than a focused oncolytic virus pure-play.

8Oncorus
TypeEmerging player
Description

Oncorus is an early-stage biotech developing intratumorally administered oncolytic virus therapies (ONCR-177) leveraging synthetic biology. It is a meaningful emerging peer in the engineered oncolytic virus modality despite having a broader tumor-type focus than DNAtriX.

9Aettis Therapeutics
TypeEmerging player
Description

Aettis is a private early-stage biotech developing oncolytic virus and immuno-oncology approaches. It is a smaller, niche emerging peer in the same modality with limited but partial overlap with DNAtriX's viral immunotherapy approach.

TypeEmerging player
Description

Alaunos Therapeutics (formerly Ziopharm Oncology) is a clinical-stage gene and cell therapy company with a Sleeping Beauty transposon platform that has historically engaged in glioma trials. It represents an emerging peer at the intersection of gene therapy and CNS oncology.

Market position
Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds13 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

DNAtriX

Oncolytic Virotherapy / Oncology Biopharmaceuticalsdnatrix.com

DNAtriX is a Houston-based clinical-stage biotechnology company developing an oncolytic virus platform to treat malignant glioma. Founded in 2005, it has raised approximately $57M in venture funding led by Morningside and DFJ Mercury to advance its engineered virus immunotherapy.

DNAtriX firmographics

Firmographics
Name
DNAtriX
Website
https://dnatrix.com
Company type
Private
Founded year
2005
Headcount range
1–10 employees
Short description
DNAtriX is a Houston-based clinical-stage biotechnology company developing an oncolytic virus platform to treat malignant glioma. Founded in 2005, it has raised approximately $57M in venture funding led by Morningside and DFJ Mercury to advance its engineered virus immunotherapy.
Ownership category
akta.pro rank

DNAtriX industry classification

Industry
Product category
Oncolytic Virotherapy / Oncology Biopharmaceuticals
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAACAF
Oncology Gene Therapies (incl. oncolytic vectors & gene-modified approaches)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAKAFAH
Neuro-Oncology
SECONDARYHLAKAFAB
Medical Oncology
SECONDARYHLAKAIAL
Neuro-oncology

Keywords

  • Oncolytic virotherapy
  • Malignant glioma treatment
  • Glioblastoma therapeutics
  • Tumor-selective adenovirus
  • Brain tumor biotechnology

Where DNAtriX is headquartered

Location

Headquarters

HQ city
San Diego
HQ country
United States
HQ region
North America

Markets served

DNAtriX business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Operations, Others

DNAtriX product offering

Product offering

Core offering

DNAtriX is a biotechnology company developing an oncolytic virus platform for treating malignant glioma. The platform uses tumor-selective viruses designed to infect and destroy cancer cells in the brain while sparing healthy tissue, addressing a high-need oncology indication with limited current treatment options.

Differentiator

Problem solved

Functional benefit

Products and services

  • DNAtriX Oncolytic Virus Platform (malignant glioma program)

Companies that use DNAtriX

Customer profile

Ideal customer profiles1 record

DNAtriX technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

DNAtriX competitors and assessment

Company assessment

Direct peers

  • Replimune: Replimune is a clinical-stage biotech developing a proprietary oncolytic virus platform (RP1, RP2, RP3) for solid tumors. Like DNAtriX, it builds tumor-selective oncolytic immunotherapies, advancing them both as monotherapy and in combination with checkpoint inhibitors - the most direct strategic comparable in the space.
  • Candel Therapeutics: Candel Therapeutics (formerly Advantagene) develops oncolytic virus and gene-mediated immunotherapy platforms including CAN-2409 for brain tumors and prostate cancer. It is one of the closest US-based clinical-stage competitors to DNAtriX in the glioma oncolytic virus space.
  • Tocagen (now Kite/Gilead): Tocagen developed Toca 511/Toca FC, a retroviral replicating vector for high-grade glioma, before being acquired by Kite/Gilead. It is the most direct historical precedent for an oncolytic/replicating virus approach specifically targeting malignant glioma.
  • Mustang Bio: Mustang Bio develops MB-101 (IL13Ralpha2-targeted CAR-T) and other cell/gene therapies for glioblastoma and other CNS malignancies. It represents a peer gene-therapy-for-glioma strategy, addressing the same indication using a different modality.
  • Plus Therapeutics: Plus Therapeutics develops targeted radiotherapeutics for CNS cancers including glioblastoma (Rhenium-186 NanoLiposome). It is an indirect clinical-stage peer competing for the same malignant glioma treatment paradigm with non-oncolytic modality.

Broad incumbents

  • Novocure: Novocure commercializes Tumor Treating Fields (Optune) as the standard-of-care adjunct for newly diagnosed and recurrent glioblastoma. It is the dominant incumbent in malignant glioma treatment and represents both the competitive benchmark and the combination-therapy partner universe for DNAtriX.
  • Sorrento Therapeutics: Sorrento has multiple oncology franchises including oncolytic virus, antibody, and cell therapy assets touching glioma and solid tumors. It operates as a broader incumbent in the oncology gene and viral therapy space rather than a focused oncolytic virus pure-play.

Emerging players

  • Oncorus: Oncorus is an early-stage biotech developing intratumorally administered oncolytic virus therapies (ONCR-177) leveraging synthetic biology. It is a meaningful emerging peer in the engineered oncolytic virus modality despite having a broader tumor-type focus than DNAtriX.
  • Aettis Therapeutics: Aettis is a private early-stage biotech developing oncolytic virus and immuno-oncology approaches. It is a smaller, niche emerging peer in the same modality with limited but partial overlap with DNAtriX's viral immunotherapy approach.
  • Ziopharm Oncology (now Alaunos Therapeutics): Alaunos Therapeutics (formerly Ziopharm Oncology) is a clinical-stage gene and cell therapy company with a Sleeping Beauty transposon platform that has historically engaged in glioma trials. It represents an emerging peer at the intersection of gene therapy and CNS oncology.

Market position

Customer concentration

DNAtriX social profiles

Digital presence

DNAtriX financial estimates

Financial estimate

Revenue estimate

Valuation estimate

DNAtriX leadership team

Management profile

Number of profiles

Profiles8 records

DNAtriX funding detail

Funding detail

Funding overview

Funding rounds13 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

DNAtriX M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about DNAtriX

What does DNAtriX do?

DNAtriX is a biotechnology company developing an oncolytic virus platform for treating malignant glioma. The platform uses tumor-selective viruses designed to infect and destroy cancer cells in the brain while sparing healthy tissue, addressing a high-need oncology indication with limited current treatment options.

When was DNAtriX founded?

DNAtriX was founded in 2005. It employs 1 to 10 people.

Where is DNAtriX based?

DNAtriX is headquartered in San Diego, United States, in the North America region.

Who are DNAtriX's main competitors?

Direct peers on record are Replimune, Candel Therapeutics, Tocagen (now Kite/Gilead), Mustang Bio and Plus Therapeutics. Broad incumbents are Novocure and Sorrento Therapeutics. Emerging players are Oncorus, Aettis Therapeutics and Ziopharm Oncology (now Alaunos Therapeutics).

Does DNAtriX have an API?

No public API is recorded for DNAtriX.

What industry is DNAtriX in?

DNAtriX's product category is Oncolytic Virotherapy / Oncology Biopharmaceuticals. Its primary akta.pro industry code is HLAAACAF, Oncology Gene Therapies (incl. oncolytic vectors & gene-modified approaches), with a secondary code of HLAKAFAH, Neuro-Oncology. Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireHigh-grade Glioma Market to Witness Upsurge in Growth by 2032, Predicts DelveInsight | Companies to Watch Out - BioMimetix, Bayer, MedImmune, DNAtrix, Chimerix, Bristol-Myers Squibb, Laminar, ImmunomiDelveInsight released a market report forecasting the high-grade glioma market to grow at a significant CAGR from 2019 to 2032, with the 7MM market size valued at USD 1.4 billion in 2022. The report highlights that while emerging pipeline candidates and advanced therapies drive growth, challenges such as low survival rates and blood-brain barrier penetration persist. Key companies including BioMimetix, Bayer, Chimerix, and Bristol-Myers Squibb are actively developing novel treatments for this aggressive form of cancer.PR NewswireDNAtrix Announces Oral Presentation of Positive Overall Survival Data with DNX-2401 in DIPG at the Society for Neuro-oncology (SNO) Annual MeetingDNAtrix announced positive Phase 1 clinical trial data for DNX-2401 in treating diffuse intrinsic pontine glioma (DIPG) at the Society for Neuro-oncology Annual Meeting in Boston. The study of 12 newly diagnosed DIPG patients showed a median overall survival of 17.8 months compared to 8-11 months with conventional radiation therapy, with tumor reductions reported in 75% of patients and no dose-limiting toxicities observed. DNX-2401 has received FDA Fast Track and Rare Pediatric Disease designations for DIPG and will advance toward further clinical development.BioSpaceDNAtrix Announces the Appointment of David Liebowitz, M.D., Ph.D., as Chief Medical OfficerDNAtrix appointed David Liebowitz, M.D., Ph.D., as chief medical officer, bringing over 20 years of oncology and viral vaccine experience. He previously led clinical oncology at Xencor and was CMO at Vaxart. The company's lead candidate DNX-2401 is in pivotal Phase 3 for recurrent glioblastoma.PR NewswireDNAtrix Announces the Appointment of David Liebowitz, M.D., Ph.D., as Chief Medical OfficerDNAtrix, a Houston-based biotech company developing virus-driven immunotherapies for cancer, announced the appointment of David Liebowitz, M.D., Ph.D. as its new Chief Medical Officer. Liebowitz brings over 20 years of oncology drug and viral vaccine development experience, having held senior positions at companies including Amgen, Xencor, Vaxart, and Galileo Pharmaceuticals. He will oversee the advancement of DNAtrix's pipeline, including DNX-2401 which is entering a global pivotal Phase 3 trial for recurrent glioblastoma and has received FDA Fast Track designation.PR NewswireDNAtrix to Present at the Raymond James Human Health Innovations ConferenceDNAtrix, a privately held biotech company developing virus-driven immunotherapies for cancer, announced it will present at the Raymond James Human Health Innovations Conference on June 21, 2021. The company's lead product candidate DNX-2401 is advancing into a global pivotal Phase 3 clinical study for recurrent glioblastoma and has received FDA Fast Track and Rare Pediatric Disease designations for diffuse intrinsic pontine glioma. The presentation will be webcast live and archived for 30 days.PR NewswireDNAtrix Announces First Patient Dosed in Clinical Study of DNX-2440, an OX40 Ligand Expressing Immunotherapy, in Colorectal Cancer and Other Cancers with Liver MetastasisDNAtrix announced the first patient has been dosed in a Phase 1 dose-escalation and dose-expansion study of DNX-2440, an OX40 ligand expressing oncolytic adenovirus, for patients with resectable liver metastasis from colorectal cancer and other cancers. The trial will enroll 24-30 patients who will receive two intra-tumoral injections of DNX-2440 prior to liver resection, with primary endpoints to establish safety and identify a maximum tolerated dose. Moffitt Cancer Center is conducting the study under principal investigator Dr. Daniel A. Anaya.PR NewswireDNAtrix Appoints Industry Veteran Herb Cross to its Board of DirectorsDNAtrix announced the appointment of Herb Cross, a seasoned financial and operational executive, to its board of directors. Cross brings over 20 years of executive leadership experience in life sciences, including leading Atreca's IPO in 2019 and ARMO BioSciences' acquisition by Eli Lilly for $1.6 billion. The appointment is intended to provide guidance as DNAtrix advances its clinical programs, including a pivotal Phase 3 study for DNX-2401 in recurrent glioblastoma.PR NewswireDNAtrix Announces Preclinical Data Demonstrating Anti-Tumor Activity of DNX-2401 in Models of Pediatric Tumors (AT/RT and CNS-PNET) Published in Clinical Cancer ResearchDNAtrix announced preclinical data showing that its oncolytic immunotherapy DNX-2401 demonstrates anti-tumor activity against aggressive pediatric brain tumors AT/RT and CNS-PNET, with findings published in Clinical Cancer Research. The study found that DNX-2401 generated proinflammatory immune responses and extended survival in mouse models of both early and advanced disease stages, including models of disseminated lesions. The findings provide a foundation for potential clinical translation to treat these pediatric cancers with limited therapeutic options.PR NewswireDNAtrix Announces Positive Data from Phase 2 CAPTIVE (KEYNOTE-192) Study with DNX-2401 in Patients with Recurrent Glioblastoma Highlighted in an Oral Late-Breaking Presentation During Society for NeurDNAtrix announced positive Phase 2 CAPTIVE (KEYNOTE-192) study results showing its oncolytic virus DNX-2401 combined with pembrolizumab achieved a median overall survival of 12.5 months in 42 patients with recurrent glioblastoma, compared to a historical benchmark of 7.2 months for standard-of-care treatments. The study enrolled 49 patients across multiple centers, with 11.9% achieving confirmed responses including two complete responses, and the company plans to advance the treatment regimen into a global randomized Phase 3 study. The FDA has already granted DNX-2401 Fast Track and Orphan designations, and the company is also evaluating the therapy in pediatric diffuse intrinsic pontine glioma.PR NewswireDNAtrix Announces Multiple Data Presentations, Including Late-Breaking Phase 2 CAPTIVE (KEYNOTE-192) Data in Recurrent Glioblastoma, Planned for the Society for Neuro-oncology (SNO) Annual MeetingDNAtrix announced that four abstracts on its oncolytic adenovirus platform have been accepted for presentation at the Society for Neuro-oncology Annual Meeting (November 19-21, 2020), including updated Phase 2 CAPTIVE (KEYNOTE-192) data for DNX-2401 (tasadenoturev) in recurrent glioblastoma. The late-breaking Phase 2 data will cover 49 patients evaluating DNX-2401 in combination with pembrolizumab. Additional presentations include data on DNX-2401 for diffuse intrinsic pontine glioma (DIPG) in children and DNX-2440 for colorectal cancers with liver metastasis.